Mark Pluym, MD
Pulmonary Disease · St Johnsbury, VTNPI 1942597489
Payments from drug & device makers
Across 439 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Boehringer Ingelheim$903
- Sanofi$767
- Regeneron Healthcare Solutions, Inc.$720
- GSK$584
- Amgen$448
- plus $3K from 34 others
What the payments were for
- Food & beverage$8,17899%
- Education$811%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 89 | $1,761 |
| Boehringer Ingelheim | 46 | $903 |
| Sanofi | 32 | $767 |
| Regeneron Healthcare Solutions, Inc. | 31 | $720 |
| GSK | 35 | $584 |
| Amgen | 22 | $448 |
| Mylan Specialty L.p. | 29 | $435 |
| Johnson & Johnson | 24 | $399 |
| Genentech USA, Inc. | 20 | $331 |
| Insmed, Inc. | 23 | $330 |
| UCB, Inc. | 9 | $193 |
| Electromed, Inc. | 17 | $184 |
| Philips North America LLC | 9 | $162 |
| AbbVie | 7 | $154 |
| Lilly USA, LLC | 7 | $121 |
| Grifols USA, LLC | 6 | $93 |
| Daiichi Sankyo Inc. | 3 | $64 |
| Sanofi-aventis U.S. LLC | 1 | $57 |
| Novartis | 3 | $55 |
| Baxter Healthcare | 3 | $55 |
| CSL Behring | 2 | $53 |
| Vertex | 2 | $45 |
| Merck | 2 | $31 |
| Pulmonx Corporation | 1 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Polynovo North America LLC | 1 | $24 |
| Pacira Pharmaceuticals Incorporated | 1 | $22 |
| Braintree Laboratories, Inc. | 1 | $20 |
| Intuitive Surgical | 1 | $19 |
| Axonics, Inc. | 1 | $18 |
| Circassia Inc. | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $17 |
| Celltrion USA Inc. | 1 | $16 |
| Pfizer | 1 | $15 |
| Telix Pharmaceuticals | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Convatec Inc. | 1 | $13 |
| Apria Healthcare LLC | 1 | $12 |
| Focal Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,259 in reported general payments places this provider in the 55th percentile of 25 pulmonary disease providers in Vermont.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 140 | $151,646 |
| Dupixent PenDupilumab | 29 | $118,178 |
| Spiriva RespimatTiotropium Bromide | 74 | $72,508 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 81 | $69,358 |
| Breo ElliptaFluticasone/Vilanterol | 73 | $61,840 |
| SymbicortBudesonide/Formoterol Fumarate | 82 | $34,217 |
| Incruse ElliptaUmeclidinium Bromide | 48 | $24,460 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 49 | $24,078 |
| Arnuity ElliptaFluticasone Furoate | 42 | $17,748 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 53 | $13,914 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $12,521 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 345 | $9,695 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 58 | $9,615 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 23 | $6,997 |
| BreynaBudesonide/Formoterol Fumarate | 34 | $5,824 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta | $584 | $293,685405 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,761 | $103,574163 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $903 | $85,02988 claims |
| PfizerAbrysvo | $15 | $3,46013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 25 pulmonary disease providers in Vermont.
Other pulmonary disease in St Johnsbury
- Brittany DucheneSt Johnsbury$0
- Charlotte TenebackBurlington$1.1M
- Daniel WeissBurlington$616K
- Anne DixonBurlington$555K
- Ena GuptaBurlington$198K
- Marta KokoszynskaBurlington$173K
- Jessica BadlamBurlington$166K
- Charles KinseyBurlington$147K
- Prema MenonBurlington$88K
- Frank DrescherWhite River Junction$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.